Latest news with #EmilyField
CNBC
10-06-2025
- Health
- CNBC
Field: Vaccine fatigue has caused flu vaccination rates to fall slightly
Emily Field, Barclays head of European pharma research, discusses RFK Jr.'s call to overhaul the CDC vaccine panel, vaccine skepticism, and the impact on stocks like Merck amid new RSV vaccine approvals.
Straits Times
08-06-2025
- Health
- Straits Times
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy. PHOTO: REUTERS Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's (EMA) safety committee said on June 6 . In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy (Naion). This is the first time a regulator has confirmed the side effect. The condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as in Novo's other diabetes drug Rybelsus, for at least one year, the regulator said. Naion is the second-most common cause of blindness due to optic nerve damage, after glaucoma. 'This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I don't see this as making any major difference to prescribing patterns,' said Barclays analyst Emily Field. US-listed shares of the Danish drugmaker were up nearly 2.5 per cent in early trading. The EMA, which started its review in December, has asked Novo to add Naion as a side effect of very rare frequency in the product information accompanying drugs that contain semaglutide. Novo said it would work with the EMA to update the labels, adding clinical trials and after-market studies did not suggest a reasonable possibility that the drugs caused the condition. The 'benefit-risk profile of semaglutide remains favourable', the company said in a statement. Novo has recently faced investor concerns that it is losing its first-mover advantage in the highly competitive obesity treatment market, leading the company to oust chief executive Lars Fruergaard Jorgensen in May. Wegovy and Eli Lilly's Zepbound currently dominate the weight-loss drug market, potentially worth about US$150 billion (S$193 billion) by the next decade. The EMA said several large studies in type-2 diabetes patients have suggested that use of Novo's drugs could raise the risk of developing Naion by twofold. A study of nearly 350,000 diabetes patients published in March showed that the risk of developing Naion more than doubled after two years of treatment with Ozempic, compared with patients taking medicines from other classes. The US Department of Health and Human Services did not immediately respond to a Reuters request for comment on whether the Food and Drug Administration was conducting a probe into the side effect. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Insider
31-05-2025
- Business
- Business Insider
Barclays Remains a Buy on Sanofi (SNYNF)
Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) yesterday and set a price target of €125.00. The company's shares closed yesterday at $99.97. Confident Investing Starts Here: Field covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Roche Holding AG. According to TipRanks, Field has an average return of -1.5% and a 39.02% success rate on recommended stocks. In addition to Barclays, Sanofi also received a Buy from Bank of America Securities's Sachin Jain in a report issued yesterday. However, on the same day, J.P. Morgan maintained a Hold rating on Sanofi (Other OTC: SNYNF).
Yahoo
30-05-2025
- Business
- Yahoo
Regeneron shares slide on mixed trial data on smoker's lung drug
(Reuters) -Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. Regeneron and partner Sanofi were studying the potential blockbuster drug, itepekimab, as a treatment for chronic obstructive pulmonary disease (COPD) in adult former smokers. The condition has limited treatment options and the drug was expected to target a broader patient population compared to Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition. But after Friday's data, Barclays analyst Emily Field said Dupixent is likely to remain the first choice for doctors. GSK's Nucala, approved recently for COPD, is also a blockbuster drug. Nearly 16 million U.S. adults suffer from COPD, according to government data. Regeneron's shares, which have already fallen 15% this year, were trading at $530 in premarket trading. The company has a market capitalization of $65.36 billion. The company's itepekimab showed a significant reduction in exacerbations or flare-ups in the condition by 27% compared to placebo at 52 weeks in a 1,127-patient study. But the second study - which had enrolled fewer former smokers compared to the first - did not meet its goal although a benefit was seen earlier in the trial. The experimental drug, which is being jointly developed by Regeneron and Sanofi, binds to and inhibits interleukin-33, a type of protein that causes inflammation in COPD. COPD is a common lung disease causing restricted airflow and breathing problems. It typically affects smokers, but can also be caused by pollutants. Sanofi and Regeneron are assessing the data and will discuss with regulatory authorities to evaluate their next steps, the companies said. Regeneron's price to earnings ratio, a common benchmark for valuing stocks, was 16.15, compared with 13.62 for Gilead and 7.29 for Bristol Myers Squibb. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
14-05-2025
- Business
- CNBC
Trump's drug pricing executive order is a 'bargaining chip' with big pharma
Emily Field, head of European pharmaceutical research at Barclays, says U.S. President Donald Trump's executive order on drug pricing marks the start of negotiations with pharmaceutical companies.
